Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study.
Adult
Aged
Case-Control Studies
Cohort Studies
Early Detection of Cancer
Female
Humans
Immunosuppressive Agents
/ therapeutic use
Incidence
Inflammatory Bowel Diseases
/ complications
Middle Aged
Neoplasm Grading
Netherlands
Papanicolaou Test
Patient Compliance
Risk Factors
Uterine Cervical Neoplasms
/ diagnosis
Uterine Cervical Dysplasia
/ diagnosis
Inflammatory bowel disease
cervical intraepithelial neoplasia
human papillomavirus
Journal
Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676
Informations de publication
Date de publication:
25 Sep 2021
25 Sep 2021
Historique:
pubmed:
21
2
2021
medline:
2
2
2022
entrez:
20
2
2021
Statut:
ppublish
Résumé
Women with inflammatory bowel disease [IBD] may be at higher risk for cervical intraepithelial neoplasia [CIN]. However, data are conflicting. The aim of this study was to assess the risk of high-grade dysplasia and cancer [CIN2+] in IBD women and identify risk factors. Clinical data from adult IBD women in a multicentre Dutch IBD prospective cohort [PSI] from 2007 onwards were linked to cervical cytology and histology records from the Dutch nationwide cytology and pathology database [PALGA], from 2000 to 2016. Patients were frequency-matched 1:4 to a general population cohort. Standardised detection rates [SDR] were calculated for CIN2+. Longitudinal data were assessed to calculate CIN2+ risk during follow-up using incidence rate ratios [IRR] and risk factors were identified in multivariable analysis. Cervical records were available from 2098 IBD women [77%] and 8379 in the matched cohort; median follow-up was 13 years. CIN2+ detection rate was higher in the IBD cohort than in the matched cohort (SDR 1.27, 95% confidence interval [CI] 1.05-1.52). Women with IBD had an increased risk of CIN2+ [IRR 1.66, 95% CI 1.21-2.25] and persistent or recurrent CIN during follow-up (odds ratio [OR] 1.89, 95% CI 1.06-3.38). Risk factors for CIN2+ in IBD women were smoking and disease location (ileocolonic [L3] or upper gastrointestinal [GI] [L4]). CIN2+ risk was not associated with exposure to immunosuppressants. Women with IBD are at increased risk for CIN2+ lesions. These results underline the importance of human papillomavirus [HPV] vaccination and adherence to cervical cancer screening guidelines in IBD women, regardless of exposure to immunosuppressants.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Women with inflammatory bowel disease [IBD] may be at higher risk for cervical intraepithelial neoplasia [CIN]. However, data are conflicting. The aim of this study was to assess the risk of high-grade dysplasia and cancer [CIN2+] in IBD women and identify risk factors.
METHODS
METHODS
Clinical data from adult IBD women in a multicentre Dutch IBD prospective cohort [PSI] from 2007 onwards were linked to cervical cytology and histology records from the Dutch nationwide cytology and pathology database [PALGA], from 2000 to 2016. Patients were frequency-matched 1:4 to a general population cohort. Standardised detection rates [SDR] were calculated for CIN2+. Longitudinal data were assessed to calculate CIN2+ risk during follow-up using incidence rate ratios [IRR] and risk factors were identified in multivariable analysis.
RESULTS
RESULTS
Cervical records were available from 2098 IBD women [77%] and 8379 in the matched cohort; median follow-up was 13 years. CIN2+ detection rate was higher in the IBD cohort than in the matched cohort (SDR 1.27, 95% confidence interval [CI] 1.05-1.52). Women with IBD had an increased risk of CIN2+ [IRR 1.66, 95% CI 1.21-2.25] and persistent or recurrent CIN during follow-up (odds ratio [OR] 1.89, 95% CI 1.06-3.38). Risk factors for CIN2+ in IBD women were smoking and disease location (ileocolonic [L3] or upper gastrointestinal [GI] [L4]). CIN2+ risk was not associated with exposure to immunosuppressants.
CONCLUSIONS
CONCLUSIONS
Women with IBD are at increased risk for CIN2+ lesions. These results underline the importance of human papillomavirus [HPV] vaccination and adherence to cervical cancer screening guidelines in IBD women, regardless of exposure to immunosuppressants.
Identifiants
pubmed: 33609353
pii: 6145789
doi: 10.1093/ecco-jcc/jjab036
pmc: PMC8653760
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1464-1473Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.
Références
Am J Gastroenterol. 2008 Mar;103(3):631-6
pubmed: 17941962
Hum Vaccin Immunother. 2014;10(7):2109-11
pubmed: 25424825
Nat Rev Cancer. 2014 Jun;14(6):395-405
pubmed: 24854082
Int J Cancer. 2014 Jul 15;135(2):453-66
pubmed: 24338632
Eur J Cancer. 2020 Jan;124:102-109
pubmed: 31760309
J Crohns Colitis. 2020 Jan 1;14(1):4-22
pubmed: 31711158
Inflamm Bowel Dis. 2013 Jun;19(7):1441-9
pubmed: 23567780
Clin Gastroenterol Hepatol. 2015 Apr;13(4):693-700.e1
pubmed: 25086189
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Aliment Pharmacol Ther. 2008 Sep 1;28(5):598-605
pubmed: 18549465
J Natl Cancer Inst. 1995 Jun 7;87(11):796-802
pubmed: 7791229
Vaccine. 2006 Mar 30;24 Suppl 1:S16-22
pubmed: 16219398
J Crohns Colitis. 2014 Jan;8(1):31-44
pubmed: 23721759
Am J Gastroenterol. 2013 Dec;108(12):1869-76
pubmed: 23978954
J Gastroenterol. 2013 Jun;48(6):713-20
pubmed: 23124604
Inflamm Bowel Dis. 2015 May;21(5):1089-97
pubmed: 25895005
Cell Oncol. 2007;29(1):19-24
pubmed: 17429138
Epidemiology. 1998 May;9(3):346-9
pubmed: 9583429
Inflamm Bowel Dis. 2011 Aug;17(8):1741-50
pubmed: 21744429
J Low Genit Tract Dis. 2019 Apr;23(2):87-101
pubmed: 30907775
Inflamm Bowel Dis. 2009 Nov;15(11):1621-9
pubmed: 19618462
Am J Clin Pathol. 1982 Sep;78(3):328-36
pubmed: 7113969
Am J Gastroenterol. 2017 Feb;112(2):241-258
pubmed: 28071656
Ann Rheum Dis. 2015 Jul;74(7):1360-7
pubmed: 24618265
BMJ Open. 2017 Nov 8;7(11):e016695
pubmed: 29122790
Clin Gastroenterol Hepatol. 2009 May;7(5):549-53
pubmed: 18996498
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
World J Gastroenterol. 2006 Oct 14;12(38):6167-71
pubmed: 17036389
J Gynecol Oncol. 2017 Sep;28(5):e47
pubmed: 28657217
Obstet Gynecol. 2008 Dec;112(6):1327-1334
pubmed: 19037043
Ann Oncol. 2010 Mar;21(3):448-458
pubmed: 20176693
Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A
pubmed: 16151544
J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S1-S27
pubmed: 23519301
Clin Microbiol Rev. 2012 Apr;25(2):215-22
pubmed: 22491770
Gastroenterology. 2009 Feb;136(2):451-8
pubmed: 18996382
JAMA. 2001 Dec 26;286(24):3106-14
pubmed: 11754676
Am J Gastroenterol. 2009 Oct;104(10):2524-33
pubmed: 19532125
Eur J Gastroenterol Hepatol. 2016 Sep;28(9):1065-72
pubmed: 27281507
Int J Cancer. 2007 Feb 15;120(4):885-91
pubmed: 17131323
JAMA. 2002 Apr 24;287(16):2114-9
pubmed: 11966386
J Natl Cancer Inst. 2010 Mar 3;102(5):315-24
pubmed: 20157096